Opus Genetics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Opus Genetics, Inc. (IRD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2017-02-24
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-12-31 was $0.00.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-09-30 was $0.00.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-06-30 was $0.00, a 100.00% decline year-over-year.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-03-31 was $0.00, a 100.00% decline year-over-year.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2015 was $99.89K, a 13.53% decline from fiscal 2014.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2014 was $115.53K, a 26.54% increase from fiscal 2013.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2013 was $91.30K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $0.00 derived: sum of 2 quarters · filed 2017-02-24 | $0.00 derived: sum of 3 quarters · filed 2017-02-24 | $0.00 10-K · filed 2017-02-24 |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-04 | $0.00 derived: sum of 2 quarters · filed 2016-11-04 | $0.00 10-Q · filed 2016-11-04 | $0.00 derived: sum of 4 quarters · filed 2017-02-24 |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-05 | $0.00 10-Q · filed 2016-08-05 | $0.00 derived: sum of 3 quarters · filed 2017-02-24 | $0.00 derived: sum of 4 quarters · filed 2017-02-24 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-06 | $0.00 derived: sum of 2 quarters · filed 2017-02-24 | $0.00 derived: sum of 3 quarters · filed 2017-02-24 | $1.84K derived: sum of 4 quarters · filed 2017-02-24 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $0.00 derived: sum of 2 quarters · filed 2017-02-24 | $1.84K derived: sum of 3 quarters · filed 2017-02-24 | $99.89K 10-K · filed 2017-02-24 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $1.84K derived: sum of 2 quarters · filed 2016-11-04 | $99.89K 10-Q · filed 2016-11-04 | $99.89K derived: sum of 4 quarters · filed 2017-02-24 |
| 2015-06-30 | $1.84K 10-Q · filed 2016-08-05 | $99.89K 10-Q · filed 2016-08-05 | $99.89K derived: sum of 3 quarters · filed 2017-02-24 | $99.89K derived: sum of 4 quarters · filed 2017-02-24 |
| 2015-03-31 | $98.05K 10-Q · filed 2016-05-06 | $98.05K derived: sum of 2 quarters · filed 2017-02-24 | $98.05K derived: sum of 3 quarters · filed 2017-02-24 | $146.18K derived: sum of 4 quarters · filed 2017-02-24 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $0.00 derived: sum of 2 quarters · filed 2017-02-24 | $48.13K derived: sum of 3 quarters · filed 2017-02-24 | $115.53K 10-K · filed 2017-02-24 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $48.13K derived: sum of 2 quarters · filed 2015-11-02 | $115.53K 10-Q · filed 2015-11-02 | $96.25K derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | $48.13K 10-Q · filed 2015-08-07 | $115.53K 10-Q · filed 2015-08-07 | $96.25K derived: sum of 3 quarters · filed 2016-03-14 | $187.55K derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | $48.13K 10-Q · filed 2015-05-08 | $48.13K derived: sum of 2 quarters · filed 2016-03-14 | $139.43K derived: sum of 3 quarters · filed 2016-03-14 | $139.43K derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $91.30K derived: sum of 2 quarters · filed 2016-03-14 | $91.30K derived: sum of 3 quarters · filed 2016-03-14 | $91.30K 10-K · filed 2016-03-14 |
| 2013-09-30 | $91.30K 10-Q · filed 2014-11-12 | $91.30K derived: sum of 2 quarters · filed 2014-11-12 | $91.30K 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $0.00 10-Q · filed 2014-08-13 | $0.00 10-Q · filed 2014-08-13 | ||
| 2011-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-22 | $69.20K derived: sum of 2 quarters · filed 2013-03-22 | $163.45K 10-K · filed 2013-03-22 | |
| 2011-09-30 | $9.20K 10-Q · filed 2012-11-08 | $103.45K 10-Q · filed 2012-11-08 | ||
| 2011-06-30 | $94.25K 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |